Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Midazolam, ATC N03AE02 für die Zeit 01.07.2026 - 30.06.2028 (zzgl. Verlängerungsoption 1x12 Monate)

Section 130a, paragraph 8, of the German Social Code (SGB V) allows health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the German Competition Act (GWB) is carried out by DAK-Gesundheit. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, containing the active substance Midazolam, ATC N03AE02, DAK-Gesundheit intends to conclude medicines discount agreements with as many interested pharmaceutical companies as possible until the entry into force of new medicines discount agreements. A discount agreement under the approval model for the aforementioned active substance will enter into force for the first time on 01.07.2026 and will end on 30.06.2028 (plus extension option 1x12 months). It will automatically end, regardless, with the entry into force of the exclusive contract.